Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052217 | 0.85 | KDM4E (0.35) | KDM4ENR3C1 | |
| SCHEMBL28813721 | 0.71 | — | — | |
| SCHEMBL7081435 | 0.71 | KMT2A (0.37) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6771509 | 0.70 | — | — | |
| SCHEMBL3979458 | 0.70 | ALDH1A1 (0.35) | ALDH1A1KDM4EMEN1NPC1TP53 | |
| SCHEMBL7260793 | 0.68 | KCNH2 (0.34) | ALDH1A1KDM4EKMT2AHSD17B10 | |
| SCHEMBL6772665 | 0.68 | — | — | |
| SCHEMBL8542575 | 0.68 | PTGIR (0.33) | — | |
| SCHEMBL9052253 | 0.68 | MMP2 (0.38) | ALDH1A1NPC1RAB9AHPGDNR3C1 | |
| SCHEMBL7461297 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000482-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2021-04-21 | — | — | EP | disclosed |
| CN-104311657-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111560060-A | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-104327182-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-9556250-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-01-31 | — | — | US | disclosed |
| EP-3000482-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2016-03-30 | — | — | EP | disclosed |
| EP-2513140-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2015-11-04 | — | — | EP | disclosed |
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-06-26 | — | — | US | disclosed |
| US-8648041-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2014-02-11 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NORDISK A/S (DK) | 2012-12-27 | — | — | US | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, GCG | ALDH1A1 2522/4885KDM4E 264/4885KEAP1 2260/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | ALDH1A1 2799/4885KDM4E 157/4885KEAP1 1642/4885 |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, GCG, DPP7 | ALDH1A1 936/4885KDM4E 111/4885KEAP1 3247/4885 |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | GLP1R, GIPR, GCGR | ALDH1A1 3576/4885KDM4E 1672/4885KEAP1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.